Literature DB >> 29715314

The burden of acute respiratory infections in Ecuador 2011-2015.

Wilson Chicaiza-Ayala1, Aquiles R Henríquez-Trujillo1, Esteban Ortiz-Prado1,2, Richard W Douce3, Marco Coral-Almeida1.   

Abstract

BACKGROUND: Burden of disease studies intend to improve public health decision-making and to measure social and economic impact in population. The objective of this study was to describe the burden of acute respiratory infections (ARI) in Ecuador between 2011 and 2015.
METHODS: Five-year period morbidity and mortality data available from national agencies of statistics was analyzed to estimate the burden of disease attributable to acute respiratory infections. Cases and deaths registered were grouped according to their ICD-10 code into three diagnostic groups: Acute upper respiratory infections (J00-J06), Influenza and pneumonia (J09-J18), and Bronchitis and other acute lower respiratory infections (J20-J22, J85, J86). Disability-adjusted life years stratified by diagnostic and age group were calculated using the "DALY" package for R. The productivity loss in monetary terms was estimated using the human capital method.
RESULTS: Over the 5-year period studied there were a total of 14.84 million cases of acute respiratory infections, with 17 757 deaths reported (0.12%). The yearly burden of disease ranged between 98 944 to 118 651 disability-adjusted life years, with an estimated average loss of productivity of US$152.16 million (±19.6) per year. Approximately 99% of the burden can be attributed to years life lost due to premature mortality in population under 5 years old and over 60 years-old.
CONCLUSIONS: The burden of acute respiratory infections remained steady during the analyzed period. Evidence-based prevention and control policies to tackle acute respiratory infections in Ecuador should focus on the population at extreme ages of life.

Entities:  

Mesh:

Year:  2018        PMID: 29715314      PMCID: PMC5929540          DOI: 10.1371/journal.pone.0196650

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


Introduction

Respiratory infections are the greatest single contributor to the overall burden of disease in the world[1,2]. Despite a small decrease of 3.2%, the global burden of lower respiratory infections continues to be the third leading cause of death in 2015 worldwide[3]. According to the Global Burden of Disease study lower respiratory infections are the leading cause of Years of Life Lost (YLL) in Ecuador [3]. The Ecuadorian National Institute for Statistics and Censuses (INEC) reported Influenza and pneumonia (ICD-10 codes J09-J18) as the fifth leading cause of death[4]. Burden estimation of pneumonia and other acute respiratory infections remains an urgent need in order to evaluate their impact and to assess the cost-effectiveness of public health interventions[5]. In Ecuador, as in other tropical latitudes, the absence of a well-defined flu season, the coexistence of other respiratory viruses and the variability of clinical presentation of acute respiratory infections, predispose health services to underestimate the burden of acute respiratory infections (ARI)[6]. Despite pre-pandemic reports of viral activity in Ecuador[7] and viral identification through notification to the Ministry of Health of Ecuador, available studies do not allow the estimation of the burden of influenza or Influenza-like Illnesses (ILI) in Ecuador. Same as in ILI, definition and diagnosis of other viruses and bacterial infections is not strong enough to characterize the attribution of burden. Considering these limitations, we propose the estimation of burden of acute respiratory disease in order to assess an approximation of the impact of this set of diseases using national databases available during the 2011–2015 period.

Materials and methods

Geographical location and study population

Ecuador is a Latin American country located in the Pacific coast of South America. This country has a continental territory and the Galapagos Islands. The continental territory is divided by the Andes Mountains in three different regions: coastal, highlands and Amazonia. In general, there is little seasonal temperature variations through the year in each region, but there is a wide variation of climate characteristics between regions. The coast and the Amazonia are characterized as tropical rainforest and highlands as temperate regions. INEC estimated that Ecuador population for 2016 was 16.5 million people (49.5% male and 50.5% female). Most people live in urban areas (63.3%). INEC estimated regional distribution of population as follows: Coastal 49.6%, highlands 44.7%, Amazonia 5.3% and 0.2% Galapagos Islands. 0.2% population live in non-delimited areas. Thirty percent of people are less than 15 years old. Ecuador has the highest population density in the region with an average of 54.5 habitants per km2.[8]

Sources of information

We use available data from the national registries of deaths, hospital discharges, and ambulatory consultations published by the INEC, and the Ecuadorian Ministry of Health in the 2011–2015 period[4]. Cases and deaths registered were grouped according to their ICD-10 code (Table 1) into the following diagnostic groups: Acute upper respiratory infections (J00-J06), Influenza and pneumonia (J09-J18), Bronchitis and other acute lower respiratory infections (J20-J22)[9].
Table 1

Diagnoses, by ICD10 code, included in the study.

ICD-10 codeDescription
J00–J06Acute upper respiratory infections
J00Acute nasopharyngitis (common cold)
J01Acute sinusitis
J02Acute pharyngitis
J03Acute tonsillitis
J04Acute laryngitis and tracheitis
J05Acute obstructive laryngitis (croup) and epiglottitis
J06Acute upper respiratory infections of multiple and unspecified sites
J09–J18Influenza and pneumonia
J09Influenza due to identified zoonotic or pandemic influenza virus
J10Influenza due to identified seasonal influenza virus
J11Influenza, virus not identified
J12Viral pneumonia, not elsewhere classified
J13Pneumonia due to Streptococcus pneumoniae
J14Pneumonia due to Haemophilus influenzae
J15Bacterial pneumonia, not elsewhere classified
J16Pneumonia due to other infectious organisms, not elsewhere classified
J17Pneumonia in diseases classified elsewhere
J18Pneumonia, organism unspecified
J20–J22Other acute lower respiratory infections
J20Acute bronchitis
J21Acute bronchiolitis
J22Unspecified acute lower respiratory infection
J85-J86Suppurative and necrotic conditions of lower respiratory tract
J85Abscess of lung and mediastinum
J86Pyothorax

ICD-10, International Statistical Classification of Diseases and Related Health Problems 10th Revision.

ICD-10, International Statistical Classification of Diseases and Related Health Problems 10th Revision. Outpatient data were obtained from the Automated Daily Register of Ambulatory Consultations (Registro Diario Automatizado de Consultas y Atenciones Ambulatorias—RDACAA) provided by the Ministry of Health since year 2013. Based on this information, an outpatient to inpatient ratio was estimated. This ratio allowed extrapolation from hospitalized cases to total cases for years 2011 and 2012[10]. Information from ambulatory consultations, hospital discharges, and deaths registries was tabulated by ICD code, sex and age group to calculate incidence and mortality rates. Incidence and mortality rates per 1000 population were calculated with a level of confidence of 95%. Ethical approval was not required for this study. Information used in this analysis came from freely available public databases published by the INEC and the Ecuadorian Ministry of Health. Anonymity of clinical records is guaranteed by legal mandate and their use is authorized for research and academic purposes while keeping confidentiality (“REGLAMENTO DE INFORMACION CONFIDENCIAL EN SISTEMA NACIONAL DE SALUD” available at: http://instituciones.msp.gob.ec/cz6/images/lotaip/Enero2015/Acuerdo%20Ministerial%205216.pdf).

Estimation of the burden of disease

The burden of disease attributable to acute respiratory infections for each year of the study period, was measured in disability-adjusted life years (DALYs) as summary measure following the methods described by Murray et al. [11]. Calculations were made using the “DALY” package for R [12]. DALYs are the sum of years lived with disability (YLDs) and years of life lost due to premature mortality (YLLs). Following an incidence perspective, YLDs were estimated as the product of the number of incident cases times the duration of disease symptoms in years, and the disability weight attributed to the disease. To estimate the disease duration, we calculated the average hospital length of stay based on the reports obtained from the databases and from available literature [13,14]. 0.0192 years for J00-J06, 0.041 years for J20-J22 and 0.0274 years for J09-J018, J85-J86. Disability weights (DW) for each disease group were assigned accordingly to the estimates by the Global Burden of Disease 2013 study: mild acute episode DW = 0.006 (95% CI 0.002–0.012) for ICD-10 codes J00-J06; moderate acute episode DW = 0.051 (95% CI 0.032–0.074) for ICD-10 codes J20-J22; and severe acute episode DW = 0.133 (95% CI 0.088–0.190) for ICD-10 codes J09-J18, J85-J86[15]. YLLs were estimated as the product of the number of deaths and the residual life expectancy at the age of death. To estimate residual life expectancy we used the Coale and Demeny model life table West, with a life expectancy at birth of 80 years for males and 82.5 years for females[11]. YLLs were also calculated using the WHO Life tables 2011–2015 estimates for Ecuador[16]. A time discount rate of 3% without age weighting was used in the calculations[11]. The economic burden was estimated following the human capital method[17], as the indirect costs generated by the productivity losses, valued in current US dollars, due to the absenteeism of the economically active patient, or the productivity loss of one caregiver in the case of minors and the elderly. Indirect costs included the loss of resources due to morbidity and mortality, considering the minimum monthly wage of a formal worker in Ecuador valued in US$ 516.25 [18]. It was not possible to perform a claims-based examination of health care costs because of the lack of electronic health records and billing systems in the public sector.

Statistical analysis

The statistical differences for mortality rates between age groups were assessed using the Poisson test. The differences of the contribution of DALYs by age group were assessed using the proportion test with the “Bonferroni” correction for multiple comparisons. To assess the seasonality of events, a regression analysis using the “tslm” function of the “forecast” package in R version 3.3.3 was used. Statistical significance was assumed for all the analysis with a p-value inferior to 0.05.

Results

Over the 5-year period studied there were a total of 14.84 million cases of acute respiratory infections with 17 757 deaths reported (0.12%). About 17 241 deaths (97.2%) were attributed to influenza or pneumonia (ICD-10 codes J09-J18). Significant differences were observed among the mortality rates across all age categories (p<0.00005). Mortality rates during the studied period were higher in the over60 years-old age group being 6 to 9 times higher than in the population under 5 years-old, the other age categories had statistically significant lower rates (p<0.00005). Seasonality was observed for hospitalizations from August to January (p = 0.000059) and for mortality cases from September to February (p = 0.048). There were 258 261 hospital discharges during the study period, 74.15% due to ICD-10 codes J09-J18, J85-J86. Incidence of acute upper respiratory infections (J00-J06) was higher in the age group under 5 years-old in all the periods studied. Incidence rates per 1000 population for ambulatory and hospitalized cases are presented in Tables 2 and 3 respectively, mortality rates per 1000 population are presented in Table 4.
Table 2

Incidence rates per thousand population of ambulatory cases of acute respiratory infections in Ecuador, years 2011–15.

Year—age groupICD-10: J00-J06ICD-10: J09-J18ICD-10: J20-J22
casesrate (95% CI)casesrate (95% CI)casesrate (95% CI)
2011—total3,145,286206.03 (205.8 to 206.25)165,87610.87 (10.81 to 10.92)294,52519.29 (19.22 to 19.36)
0–4 years old1,256,336741.28 (739.99 to 742.58)93,76155.32 (54.97 to 55.68)171,122100.97 (100.49 to 101.45)
5–14 years old872,052271.52 (270.95 to 272.09)28,6108.91 (8.81 to 9.01)59,84018.63 (18.48 to 18.78)
15–44 years old709,869101.94 (101.7 to 102.17)22,1673.18 (3.14 to 3.23)32,1084.61 (4.56 to 4.66)
45–59 years old169,08986.15 (85.74 to 86.56)8,1994.18 (4.09 to 4.27)12,8386.54 (6.43 to 6.65)
60 + years old137,94096.24 (95.73 to 96.75)13,1399.17 (9.01 to 9.32)18,61712.99 (12.8 to 13.18)
2012—total2,868,531184.82 (184.6 to 185.03)138,0088.89 (8.84 to 8.94)262,32716.9 (16.84 to 16.97)
0–4 years old1,131,414667.71 (666.48 to 668.95)76,82045.34 (45.02 to 45.66)150,80389 (88.55 to 89.45)
5–14 years old793,471244.71 (244.17 to 245.25)23,6787.3 (7.21 to 7.4)53,16016.39 (16.26 to 16.53)
15–44 years old658,82792.91 (92.68 to 93.13)18,6282.63 (2.59 to 2.66)29,2684.13 (4.08 to 4.17)
45–59 years old157,46377.86 (77.47 to 78.24)7,0533.49 (3.41 to 3.57)11,7885.83 (5.72 to 5.93)
60 + years old127,35686.62 (86.14 to 87.09)11,8298.05 (7.9 to 8.19)17,30811.77 (11.6 to 11.95)
2013—total2,652,401168.14 (167.94 to 168.34)115,6327.33 (7.29 to 7.37)236,25714.98 (14.92 to 15.04)
0–4 years old1,043,257616.8 (615.62 to 617.99)63,59637.6 (37.31 to 37.89)135,65880.2 (79.78 to 80.63)
5–14 years old723,580221.23 (220.72 to 221.74)19,3825.93 (5.84 to 6.01)47,04514.38 (14.25 to 14.51)
15–44 years old620,06785.9 (85.68 to 86.11)15,8222.19 (2.16 to 2.23)26,7823.71 (3.67 to 3.75)
45–59 years old147,24970.72 (70.36 to 71.08)6,0412.9 (2.83 to 2.98)10,7155.15 (5.05 to 5.24)
60 + years old118,24878.22 (77.78 to 78.67)10,7917.14 (7 to 7.27)16,05710.62 (10.46 to 10.79)
2014—total2,156,911134.58 (134.4 to 134.76)68,9584.3 (4.27 to 4.33)182,74511.4 (11.35 to 11.45)
0–4 years old801,673475.26 (474.22 to 476.3)35,21020.87 (20.66 to 21.09)99,08258.74 (58.37 to 59.11)
5–14 years old607,707184.4 (183.94 to 184.87)11,9613.63 (3.56 to 3.7)37,78311.46 (11.35 to 11.58)
15–44 years old520,12370.8 (70.61 to 71)9,3511.27 (1.25 to 1.3)22,2453.03 (2.99 to 3.07)
45–59 years old126,30858.97 (58.65 to 59.3)4,0681.9 (1.84 to 1.96)9,3084.35 (4.26 to 4.44)
60 + years old101,10064.92 (64.52 to 65.33)8,3685.37 (5.26 to 5.49)14,3279.2 (9.05 to 9.35)
2015—total2,066,451126.94 (126.77 to 127.11)57,9213.56 (3.53 to 3.59)169,31810.4 (10.35 to 10.45)
0–4 years old789,751469.67 (468.63 to 470.7)29,64017.63 (17.43 to 17.83)94,60956.26 (55.91 to 56.62)
5–14 years old555,808167.6 (167.16 to 168.04)9,0032.71 (2.66 to 2.77)32,8629.91 (9.8 to 10.02)
15–44 years old506,94767.84 (67.65 to 68.02)8,0651.08 (1.06 to 1.1)20,5002.74 (2.71 to 2.78)
45–59 years old119,19254.14 (53.83 to 54.45)3,3501.52 (1.47 to 1.57)8,1953.72 (3.64 to 3.8)
60 + years old94,75358.98 (58.61 to 59.36)7,8634.89 (4.79 to 5)13,1528.19 (8.05 to 8.33)

ICD-10, International Statistical Classification of Diseases and Related Health Problems 10th Revision; J00-J06, Acute upper respiratory infections; J09-J18, Influenza and pneumonia; J20-J22, Other acute lower respiratory infections.

Table 3

Hospitalization rates per thousand population, by age group, for acute respiratory infections in Ecuador, 2011–15.

Year—age groupICD-10: J00-J06ICD-10: J09-J18ICD-10: J20-J22ICD-10: J85-J86
casesrate (95% CI)casesrate (95% CI)casesrate (95% CI)casesrate (95% CI)
2011—total4,9000.321 (0.312 to 0.33)37,1782.435 (2.411 to 2.46)7,4410.487 (0.476 to 0.499)1920.013 (0.011 to 0.014)
0–4 years old2,4251.431 (1.374 to 1.489)19,44511.473 (11.313 to 11.636)5,4903.239 (3.154 to 3.326)450.027 (0.019 to 0.036)
5–14 years old1,0220.318 (0.299 to 0.338)3,4021.059 (1.024 to 1.095)8310.259 (0.241 to 0.277)110.003 (0.002 to 0.006)
15–44 years old1,0220.147 (0.138 to 0.156)3,6360.522 (0.505 to 0.539)4400.063 (0.057 to 0.069)550.008 (0.006 to 0.01)
45–59 years old2420.123 (0.108 to 0.14)2,1021.071 (1.026 to 1.118)1820.093 (0.08 to 0.107)410.021 (0.015 to 0.028)
60 + years old1890.132 (0.114 to 0.152)8,5935.995 (5.869 to 6.123)4980.347 (0.318 to 0.379)400.028 (0.02 to 0.038)
2012—total4,9820.321 (0.312 to 0.33)38,7212.495 (2.47 to 2.52)8,3910.541 (0.529 to 0.552)1980.013 (0.011 to 0.015)
0–4 years old2,3831.406 (1.35 to 1.464)21,35512.603 (12.434 to 12.773)6,3803.765 (3.673 to 3.859)360.021 (0.015 to 0.029)
5–14 years old1,1350.35 (0.33 to 0.371)3,7481.156 (1.119 to 1.194)9890.305 (0.286 to 0.325)100.003 (0.001 to 0.006)
15–44 years old1,0460.148 (0.139 to 0.157)2,9430.415 (0.4 to 0.43)4520.064 (0.058 to 0.07)680.01 (0.007 to 0.012)
45–59 years old2330.115 (0.101 to 0.131)1,7960.888 (0.847 to 0.93)1590.079 (0.067 to 0.092)310.015 (0.01 to 0.022)
60 + years old1850.126 (0.108 to 0.145)8,8796.039 (5.914 to 6.166)4110.28 (0.253 to 0.308)530.036 (0.027 to 0.047)
2013—total6,8590.435 (0.425 to 0.445)42,5252.696 (2.67 to 2.722)8,2290.522 (0.51 to 0.533)1660.011 (0.009 to 0.012)
0–4 years old3,6542.16 (2.091 to 2.232)22,35013.214 (13.041 to 13.388)6,0213.56 (3.47 to 3.651)240.014 (0.009 to 0.021)
5–14 years old1,4860.454 (0.432 to 0.478)3,6401.113 (1.077 to 1.15)1,0300.315 (0.296 to 0.335)140.004 (0.002 to 0.007)
15–44 years old1,2150.168 (0.159 to 0.178)3,7350.517 (0.501 to 0.534)4910.068 (0.062 to 0.074)660.009 (0.007 to 0.012)
45–59 years old2590.124 (0.11 to 0.14)2,5421.221 (1.174 to 1.269)2160.104 (0.09 to 0.119)240.012 (0.007 to 0.017)
60 + years old2450.162 (0.142 to 0.184)10,2586.786 (6.655 to 6.918)4710.312 (0.284 to 0.341)380.025 (0.018 to 0.035)
2014—total5,7300.358 (0.348 to 0.367)37,4652.338 (2.314 to 2.361)7,6960.48 (0.47 to 0.491)1790.011 (0.01 to 0.013)
0–4 years old3,0231.792 (1.729 to 1.857)19,67811.666 (11.503 to 11.83)5,8953.495 (3.406 to 3.585)360.021 (0.015 to 0.03)
5–14 years old1,2420.377 (0.356 to 0.398)3,1780.964 (0.931 to 0.998)7140.217 (0.201 to 0.233)80.002 (0.001 to 0.005)
15–44 years old1,0130.138 (0.13 to 0.147)2,6360.359 (0.345 to 0.373)4230.058 (0.052 to 0.063)690.009 (0.007 to 0.012)
45–59 years old2440.114 (0.1 to 0.129)1,8350.857 (0.818 to 0.897)1890.088 (0.076 to 0.102)310.014 (0.01 to 0.021)
60 + years old2080.134 (0.116 to 0.153)10,1386.51 (6.384 to 6.638)4750.305 (0.278 to 0.334)350.022 (0.016 to 0.031)
2015—total5,4510.335 (0.326 to 0.344)34,6822.13 (2.108 to 2.153)7,0600.434 (0.424 to 0.444)2160.013 (0.012 to 0.015)
0–4 years old3,0341.804 (1.741 to 1.87)17,49210.403 (10.249 to 10.558)5,3873.204 (3.119 to 3.29)280.017 (0.011 to 0.024)
5–14 years old1,1430.345 (0.325 to 0.365)3,1730.957 (0.924 to 0.991)6880.207 (0.192 to 0.224)140.004 (0.002 to 0.007)
15–44 years old8900.119 (0.111 to 0.127)2,3100.309 (0.297 to 0.322)3610.048 (0.043 to 0.054)860.012 (0.009 to 0.014)
45–59 years old1970.089 (0.077 to 0.103)1,6620.755 (0.719 to 0.792)1610.073 (0.062 to 0.085)500.023 (0.017 to 0.03)
60 + years old1870.116 (0.1 to 0.134)10,0456.253 (6.131 to 6.376)4630.288 (0.263 to 0.316)380.024 (0.017 to 0.032)

ICD-10, International Statistical Classification of Diseases and Related Health Problems 10th Revision; J00-J06, Acute upper respiratory infections; J09-J18, Influenza and pneumonia; J20-J22, Other acute lower respiratory infections; J85-J86, Suppurative and necrotic conditions of lower respiratory tract.

Table 4

Mortality rates per 10 thousand population, by age group, for acute respiratory infections in Ecuador, 2011–15.

Year—age groupICD-10: J00-J06ICD-10: J09-J18ICD-10: J20-J22ICD-10: J85-J86
deathsrate (95% CI)deathsrate (95% CI)deathsrate (95% CI)deathsrate (95% CI)
2011—total200.013 (0.008 to 0.02)3,0862.021 (1.951 to 2.094)800.052 (0.042 to 0.065)310.02 (0.014 to 0.029)
0–4 years old130.077 (0.041 to 0.131)3692.177 (1.961 to 2.411)440.26 (0.189 to 0.349)-0 (0 to 0.022)
5–14 years old-0 (0 to 0.011)730.227 (0.178 to 0.286)50.016 (0.005 to 0.036)-0 (0 to 0.011)
15–44 years old20.003 (0 to 0.01)2510.36 (0.317 to 0.408)40.006 (0.002 to 0.015)70.01 (0.004 to 0.021)
45–59 years old-0 (0 to 0.019)1840.937 (0.807 to 1.083)20.01 (0.001 to 0.037)100.051 (0.024 to 0.094)
60 + years old50.035 (0.011 to 0.081)2,20915.412 (14.776 to 16.068)250.174 (0.113 to 0.257)140.098 (0.053 to 0.164)
2012—total140.009 (0.005 to 0.015)3,6082.325 (2.249 to 2.402)1150.074 (0.061 to 0.089)180.012 (0.007 to 0.018)
0–4 years old80.047 (0.02 to 0.093)3772.225 (2.006 to 2.461)530.313 (0.234 to 0.409)10.006 (0 to 0.033)
5–14 years old10.003 (0 to 0.017)660.204 (0.157 to 0.259)50.015 (0.005 to 0.036)10.003 (0 to 0.017)
15–44 years old10.001 (0 to 0.008)2220.313 (0.273 to 0.357)60.008 (0.003 to 0.018)10.001 (0 to 0.008)
45–59 years old-0 (0 to 0.018)1980.979 (0.847 to 1.125)60.03 (0.011 to 0.065)60.03 (0.011 to 0.065)
60 + years old40.027 (0.007 to 0.07)2,74518.669 (17.977 to 19.381)450.306 (0.223 to 0.41)90.061 (0.028 to 0.116)
2013—total200.013 (0.008 to 0.02)3,7542.38 (2.304 to 2.457)730.046 (0.036 to 0.058)220.014 (0.009 to 0.021)
0–4 years old90.053 (0.024 to 0.101)3211.898 (1.696 to 2.117)260.154 (0.1 to 0.225)30.018 (0.004 to 0.052)
5–14 years old-0 (0 to 0.011)710.217 (0.17 to 0.274)20.006 (0.001 to 0.022)20.006 (0.001 to 0.022)
15–44 years old10.001 (0 to 0.008)2800.388 (0.344 to 0.436)30.004 (0.001 to 0.012)40.006 (0.002 to 0.014)
45–59 years old10.005 (0 to 0.027)2811.35 (1.196 to 1.517)50.024 (0.008 to 0.056)20.01 (0.001 to 0.035)
60 + years old90.06 (0.027 to 0.113)2,80118.529 (17.849 to 19.228)370.245 (0.172 to 0.337)110.073 (0.036 to 0.13)
2014—total50.003 (0.001 to 0.007)3,4222.135 (2.064 to 2.208)730.046 (0.036 to 0.057)190.012 (0.007 to 0.019)
0–4 years old10.006 (0 to 0.033)3181.885 (1.684 to 2.104)320.19 (0.13 to 0.268)30.018 (0.004 to 0.052)
5–14 years old-0 (0 to 0.011)470.143 (0.105 to 0.19)40.012 (0.003 to 0.031)30.009 (0.002 to 0.027)
15–44 years old-0 (0 to 0.005)2270.309 (0.27 to 0.352)40.005 (0.001 to 0.014)30.004 (0.001 to 0.012)
45–59 years old-0 (0 to 0.017)2151.004 (0.874 to 1.147)60.028 (0.01 to 0.061)-0 (0 to 0.017)
60 + years old40.026 (0.007 to 0.066)2,61516.793 (16.155 to 17.449)270.173 (0.114 to 0.252)100.064 (0.031 to 0.118)
2015—total90.006 (0.003 to 0.01)3,2712.009 (1.941 to 2.079)770.047 (0.037 to 0.059)290.018 (0.012 to 0.026)
0–4 years old20.012 (0.001 to 0.043)2611.552 (1.37 to 1.752)280.167 (0.111 to 0.241)10.006 (0 to 0.033)
5–14 years old10.003 (0 to 0.017)400.121 (0.086 to 0.164)10.003 (0 to 0.017)10.003 (0 to 0.017)
15–44 years old10.001 (0 to 0.007)1850.248 (0.213 to 0.286)30.004 (0.001 to 0.012)70.009 (0.004 to 0.019)
45–59 years old10.005 (0 to 0.025)1790.813 (0.698 to 0.941)50.023 (0.007 to 0.053)60.027 (0.01 to 0.059)
60 + years old40.025 (0.007 to 0.064)2,60616.221 (15.605 to 16.857)400.249 (0.178 to 0.339)140.087 (0.048 to 0.146)

ICD-10, International Statistical Classification of Diseases and Related Health Problems 10th Revision; J00-J06, Acute upper respiratory infections; J09-J18, Influenza and pneumonia; J20-J22, Other acute lower respiratory infections; J85-J86, Suppurative and necrotic conditions of lower respiratory tract.

ICD-10, International Statistical Classification of Diseases and Related Health Problems 10th Revision; J00-J06, Acute upper respiratory infections; J09-J18, Influenza and pneumonia; J20-J22, Other acute lower respiratory infections. ICD-10, International Statistical Classification of Diseases and Related Health Problems 10th Revision; J00-J06, Acute upper respiratory infections; J09-J18, Influenza and pneumonia; J20-J22, Other acute lower respiratory infections; J85-J86, Suppurative and necrotic conditions of lower respiratory tract. ICD-10, International Statistical Classification of Diseases and Related Health Problems 10th Revision; J00-J06, Acute upper respiratory infections; J09-J18, Influenza and pneumonia; J20-J22, Other acute lower respiratory infections; J85-J86, Suppurative and necrotic conditions of lower respiratory tract. The yearly burden of disease ranged between 99864 (97672–102093) to 119300 (116897–121712) DALYs equivalent to 6.39 (6.36–6.43) to 7.56 (7.52–7.61) DALYs per 1000 population (Table 5). In every year studied 99% of DALYs were attributed to YLLs mainly due to premature mortality by influenza and pneumonia in population under 5 years-old and over 60 years-old (Table 6). There were no significant differences in the burden of disease estimations with Coale and Demeny model life table West and WHO 2011–2015 life tables estimates for Ecuador.
Table 5

Estimated burden of acute respiratory infections in Ecuador in the period 2011–2015 (ICD10 codes: J00—J22, J85—J86).

Yearpopulation at risk—ncases—ndeaths—nYLD—n (95% CI)YLL—n (95% CI)DALY—n (95% CI)DALY—rate (95% CI)*
201115266431365540432191936 (1616–2262)97928 (95770–100126)99864 (97672–102093)6.54 (6.5–6.58)
201215520973332119937581712 (1436–2000)114308 (111989–116663)116020 (113688–118393)7.48 (7.43–7.52)
201315774749306209138711544 (1297–1802)117756 (115356–120165)119300 (116897–121712)7.56 (7.52–7.61)
201416027466245968135211122 (942–1310)107123 (104810–109427)108245 (105927–110555)6.75 (6.71–6.79)
201516278844234111133881015 (849–1187)103072 (100819–105319)104087 (101838–106349)6.39 (6.36–6.43)

ICD-10, International Statistical Classification of Diseases and Related Health Problems 10th Revision; J00-J06, Acute upper respiratory infections; J09-J18, Influenza and pneumonia; J20-J22, Other acute lower respiratory infections; J85-J86, Suppurative and necrotic conditions of lower respiratory tract.

* Rates per thousand population.

Table 6

Total DALY per sex and age group attribuitable to acute respiratory infections in Ecuador in the period 2011–2015.

Age group20112012201320142015
TotalMaleFemaleTotalMaleFemaleTotalMaleFemaleTotalMaleFemaleTotalMaleFemale
0–4 years old1400769107097142777043723411737579059471133755925745939846364762
5–14 years old27581361139725621264129825801273130718719239481504742762
15–44 years old832341054218725235773675899944394560729735993698612330203103
45–59 years old607229953077648832003288889043854505680033543446587929002979
60+ years old686973388234815854284213443294870974295744140809463992341023811994004841151
Total9985749253506041160075721858789119303588446045910825153391548601041035134652757
ICD-10, International Statistical Classification of Diseases and Related Health Problems 10th Revision; J00-J06, Acute upper respiratory infections; J09-J18, Influenza and pneumonia; J20-J22, Other acute lower respiratory infections; J85-J86, Suppurative and necrotic conditions of lower respiratory tract. * Rates per thousand population. The average annual losses due to indirect cost in current US dollars equals US$152.16 million (±19.6 millions), equivalent to 0.164% of the Gross Domestic Product of Ecuador. Total productivity losses in the five-year period studied accounts US$760.8 million. (Table 7)
Table 7

Estimated productivity losses (in current US dollars) due to acute respiratory infections in Ecuador 2001–2015.

YearAmbulatory casesHospital admissionsDeathsTotal
2011$ 93.071.796$ 6.392.363$ 73.032.856$ 172.497.014
2012$ 84.377.604$ 6.782.648$ 66.720.152$ 157.880.403
2013$ 77.548.236$ 8.126.369$ 85.583.928$ 171.258.533
2014$ 62.172.349$ 7.101.019$ 67.234.336$ 136.507.704
2015$ 59.205.873$ 6.537.248$ 56.913.464$ 122.656.585
Total$ 376.375.857$ 34.939.646$ 349.484.736$ 760.800.239

Discussion

Most of the available estimations of burden of pneumonia, acute respiratory diseases and other infectious diseases, have been done through methodologies based on analysis of systematic reviews, expert opinion, literature reviews and data extrapolation [19-21]. In 2013, Savy et al. performed a systematic review to estimate the burden of influenza in Latin America and the Caribbean. This group stated that pneumonia and influenza related deaths are most common in population age groups under5 years-old and over 60-years-old, reporting that influenza and pneumonia deaths in Ecuador were the highest in Latin America (14.4%) for the year 2003 in children under 5 years-old. Finally, they stated that underreporting and scarce information impede accurate estimation of impact of influenza in the region of Latin America and the Caribbean [22]. Available data about DALYs in Ecuador for upper and lower respiratory infections in 2015 obtained from the Institute for Health Metrics and Evaluation Global Health Data Exchange web page (IHME) [23] reports 184 053.03 DALYs (95% CI 213 970.98–162 755.42). The differences obtained between the results reported in the present study (104 103 DALY) and the estimations obtained by the IHME could be attributed to methodological differences. The overlapping clinical syndromes caused by the etiologic agents of acute respiratory infections make it difficult to assign a specific etiology based on the clinical presentations. Our approach using both hospitalized cases and ambulatory cases databases provide an estimation of burden without adjustment for other non-specific causes of morbidity and mortality. Thus, obtaining reliable population-based estimates for disease burden of respiratory infections remains a challenge. The two highest drivers of the burden of acute respiratory infections are premature deaths in the populations over 60 years-old and under 5 years-old, which produces a high number of YLL. This “U-shaped” distribution of death rates by age group is concordant with the situation reported by Lara-Oliveros et al. [24]in a low income district in Bogota, Colombia, and also compares to reports from Brazil and India [25,26]. Worldwide, acute respiratory infections were responsible for about 1.9 million pediatric deaths in 2000 [27,28]. According the Forum of International Respiratory Diseases, more than 4 million deaths annually are produced by acute respiratory infections in developing countries. This forum attributes risk factors as living in crowded conditions, malnutrition, lack of immunization, HIV and exposure to tobacco or indoor smoke [1,2]. Public health decisions concerning acute respiratory diseases should be focused in these two age groups. While partial seasonal patterns in mortality and hospitalizations were found in this study, seasonal effect and molecular characterization of circulating viruses in ambulatory consultations should be investigated in further research. A recent study on the etiology of severe pneumonia in Ecuadorian children described the association of respiratory syncytial virus, metapneumovirus, and adenovirus with severe infections [29]. In temperate regions, public health decisions about influenza immunization are defined upon viral characterizations for each region. In tropical countries it is not clear if it is necessary to follow a seasonal pattern or not. New evidence about recommendations of vaccine use in tropical regions could be implemented in Ecuador [30-32]. Seasonal influenza vaccine, conjugate pneumococcal vaccine and Pentavalent Vaccine (DPT-HepB-Hib) were administered regularly in 2007 as part of the national vaccination program [33]. Currently, the Ecuadorian vaccination scheme includes programmed immunization with these agents [34]. According to official reports, vaccine coverage has declined since 2014 until 2017 in all age groups. For instance, reported coverage in children from 6 to 11 months of age fell from 79% in the 2014–2015 period, to 46% in the 2016–2017 period. For children of 1 to 3 years-old, coverage declined from 93 to 65% and in pregnant women, it declined from 72 to 43%. In people older than 65 years-old, it declined from 100% of coverage for 2014–15 to 82% in the 2015–16 period. There is no data for this specific age group for the 2016–17 period [8]. A limitation in this study was that data before 2007 is not available to compare the impact of these interventions in matters of disease burden. Availability of public databases allows prompt use of data to assess epidemiological variables in population and decisions in public health. Existing data of acute upper respiratory infections are always underestimated because of nonspecific clinical presentation and a perceived lack of need of medical attention for a benign illness. Acute respiratory infections are directly linked to prescribed or auto-prescribed consumption of drugs. The demand for generic and brand name drugs is highly driven by non-steroidal anti-inflammatory drugs (NSAIDs), especially by those recommended for the symptoms of cold and flu [2]. In a short unpublished analysis, during 2012 to 2014, Ecuador spent more than 29.5 million USD in flu and cold medication (NSAIDs + nasal decongestant + antihistamine) representing more than 6.4 million units sold during those years. The consumption of treatment drugs is determined essentially by 1) doctors’ prescription given in ambulatory attention, 2) hospitalization and rehabilitation, and/or by 3) the user (auto-medication—auto-prescription [35]. Access to these drugs is also regulated by the economic status of the population, with the poorer group spending the most in out of pocket expenses [36]. In further research, direct and indirect costs related with acute respiratory infections should be estimated. Direct costs could not be estimated in this study because the health system in Ecuador does not have a billing system or register of direct expenses generated by medical consultation. However, our estimation of indirect costs could be an initial approach to the economic impact that acute respiratory infections produces in the economy of Ecuador.

Conclusions

Periodic analyses of the burden of diseases can stimulate the implementation of evidence-based prevention and control policies to tackle acute respiratory infections in Ecuador specially influenza and pneumonia cases at extreme ages of life. Implementation of methodic processes of estimation should be encouraged in multiple scenarios. National immunization programs are the first intervention that must be maintained in terms of coverage and quality. Activity surveillance and virological characterization of respiratory viruses especially at primary care settings need to be implemented to complement information of acute respiratory infections. Finally, widespread awareness in health services in the country about impact, management and report of acute respiratory infectious should be permanent.
  21 in total

1.  Disability weights for the Global Burden of Disease 2013 study.

Authors:  Joshua A Salomon; Juanita A Haagsma; Adrian Davis; Charline Maertens de Noordhout; Suzanne Polinder; Arie H Havelaar; Alessandro Cassini; Brecht Devleesschauwer; Mirjam Kretzschmar; Niko Speybroeck; Christopher J L Murray; Theo Vos
Journal:  Lancet Glob Health       Date:  2015-11       Impact factor: 26.763

2.  [Access to drugs and the situation of the pharmaceutical market in Ecuador].

Authors:  Esteban Ortiz-Prado; Claudio Galarza; Fernando Cornejo León; Jorge Ponce
Journal:  Rev Panam Salud Publica       Date:  2014-07

3.  WHO estimates of the causes of death in children.

Authors:  Jennifer Bryce; Cynthia Boschi-Pinto; Kenji Shibuya; Robert E Black
Journal:  Lancet       Date:  2005 Mar 26-Apr 1       Impact factor: 79.321

4.  Melanoma burden by melanoma stage: Assessment through a disease transition model.

Authors:  Isabelle Tromme; Catherine Legrand; Brecht Devleesschauwer; Ulrike Leiter; Stefan Suciu; Alexander Eggermont; Julie Francart; Frederic Calay; Juanita A Haagsma; Jean-François Baurain; Luc Thomas; Philippe Beutels; Niko Speybroeck
Journal:  Eur J Cancer       Date:  2015-12-13       Impact factor: 9.162

Review 5.  Estimates of world-wide distribution of child deaths from acute respiratory infections.

Authors:  Brian G Williams; Eleanor Gouws; Cynthia Boschi-Pinto; Jennifer Bryce; Christopher Dye
Journal:  Lancet Infect Dis       Date:  2002-01       Impact factor: 25.071

6.  Disease burden and medical cost-analysis of Acute Respiratory Infections in a low-income district of Bogotá.

Authors:  Carlos A Lara-Oliveros; Diana De Graeve; Fabián Franco; Sandra P Daza
Journal:  Rev Salud Publica (Bogota)       Date:  2016-08

Review 7.  Use of expansion factors to estimate the burden of dengue in Southeast Asia: a systematic analysis.

Authors:  Eduardo A Undurraga; Yara A Halasa; Donald S Shepard
Journal:  PLoS Negl Trop Dis       Date:  2013-02-21

8.  Sentinel surveillance of influenza-like-illness in two cities of the tropical country of Ecuador: 2006-2010.

Authors:  Richard W Douce; Washington Aleman; Wilson Chicaiza-Ayala; Cesar Madrid; Merly Sovero; Franklin Delgado; Mireya Rodas; Julia Ampuero; Gloria Chauca; Juan Perez; Josefina Garcia; Tadeusz Kochel; Eric S Halsey; V Alberto Laguna-Torres
Journal:  PLoS One       Date:  2011-08-24       Impact factor: 3.240

9.  The impact of individual-level heterogeneity on estimated infectious disease burden: a simulation study.

Authors:  Scott A McDonald; Brecht Devleesschauwer; Jacco Wallinga
Journal:  Popul Health Metr       Date:  2016-12-08

Review 10.  Burden of influenza in Latin America and the Caribbean: a systematic review and meta-analysis.

Authors:  Vilma Savy; Agustín Ciapponi; Ariel Bardach; Demián Glujovsky; Patricia Aruj; Agustina Mazzoni; Luz Gibbons; Eduardo Ortega-Barría; Rómulo E Colindres
Journal:  Influenza Other Respir Viruses       Date:  2012-12-05       Impact factor: 4.380

View more
  4 in total

1.  Incidence and seasonality of respiratory viruses among medically attended children with acute respiratory infections in an Ecuador birth cohort, 2011-2014.

Authors:  Eduardo Azziz-Baumgartner; Alfredo Bruno; Michael Daugherty; Martha E Chico; Andrea Lopez; Carmen Sofia Arriola; Domenica de Mora; Alba María Ropero; William W Davis; Meredith McMorrow; Philip J Cooper
Journal:  Influenza Other Respir Viruses       Date:  2021-08-25       Impact factor: 5.606

2.  Household Costs Associated with Hospitalization of Children with Severe Pneumonia in Quito, Ecuador.

Authors:  Lora L Sabin; Bertha Estrella; Fernando Sempértegui; Norman Farquhar; Aldina Mesic; Nafisa Halim; Chia-Ying Lin; Oswaldo Rodriguez; Davidson H Hamer
Journal:  Am J Trop Med Hyg       Date:  2020-04       Impact factor: 2.345

3.  Etiologies of outpatient medically attended acute respiratory infections among young Ecuadorian children prior to the start of the 2020 SARS-CoV-2 pandemic.

Authors:  Manika Suryadevara; Freddy Pizarro Fajardo; Cinthya Cueva Aponte; Jorge Luis Carrillo Aponte; Esteban Ortiz Prado; Ivan Hidalgo; Cynthia A Bonville; Irene Torres; Joseph B Domachowske
Journal:  Influenza Other Respir Viruses       Date:  2022-09-29       Impact factor: 5.606

4.  Seasonal influenza, its complications and related healthcare resource utilization among people 60 years and older: A descriptive retrospective study in Japan.

Authors:  Yuriko Hagiwara; Kazumasa Harada; Joshua Nealon; Yasuyuki Okumura; Takeshi Kimura; Sandra S Chaves
Journal:  PLoS One       Date:  2022-10-03       Impact factor: 3.752

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.